Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study

Obesity

Volumn 20, Issue 2, 2012, Pages 364-370

  Kelly, Aaron S ^a   Metzig, Andrea M ^a   Rudser, Kyle D ^b   Fitch, Angela K ^a   Fox, Claudia K ^a   Nathan, Brandon M ^a   M Deering, Mary ^a   Schwartz, Betsy L ^c   Abuzzahab, M Jennifer ^d   Gandrud, Laura M ^d   Moran, Antoinette ^a   Billington, Charles J ^a,e   Schwarzenberg, Sarah J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c INTERNATIONAL DIABETES CENTER   (United States)

^d CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; EXENDIN 4; GLUCOSE; INSULIN;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; BLOOD PRESSURE MEASUREMENT; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; GLUCOSE BLOOD LEVEL; HUMAN; INJECTION SITE CONTUSION; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LYMPHOCYTE FUNCTION; MALE; NAUSEA; OBESITY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MINNESOTA; OBESITY, MORBID; PEPTIDES; PILOT PROJECTS; RISK FACTORS; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME; VENOMS; WEIGHT LOSS;

EID: 84856242456     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.337     Document Type: Article

References (26)

1. Flegal KM, Wei R, Ogden CL et al. Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. Am J Clin Nutr 2009;90:1314-1320.
2. Koebnick C, Smith N, Coleman KJ et al. Prevalence of extreme obesity in a multiethnic cohort of children and adolescents. J Pediatr 2010;157: 26-31.e2.
3. Marcus MD, Baranowski T, DeBar LL et al. Severe obesity and selected risk factors in a sixth grade multiracial cohort: the HEALTHY study. J Adolesc Health 2010;47:604-607.
4. Franks PW, Hanson RL, Knowler WC et al. Childhood predictors of youngonset type 2 diabetes. Diabetes 2007;56:2964-2972. (Pubitemid 350223631)
5. Nguyen QM, Srinivasan SR, Xu JH, Chen W, Berenson GS. Changes in risk variables of metabolic syndrome since childhood in pre-diabetic and type 2 diabetic subjects: the Bogalusa Heart Study. Diabetes Care 2008;31: 2044-2049.
6. Yeung EH, Zhang C, Louis GM, Willett WC, Hu FB. Childhood size and life course weight characteristics in association with the risk of incident type 2 diabetes. Diabetes Care 2010;33:1364-1369.
7. Baker JL, Olsen LW, Sørensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007;357:2329-2337. (Pubitemid 350223387)
8. Li S, Chen W, Srinivasan SR et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003;290:2271-2276. (Pubitemid 37430559)
9. Franks PW, Hanson RL, Knowler WC et al. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 2010;362:485-493.
10. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992;327:1350-1355.
11. Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 2007;150:12-17.e2.
12. Invitti C, Guzzaloni G, Gilardini L, Morabito F, Viberti G. Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care 2003;26:118-124. (Pubitemid 36929003)
13. The NS, Suchindran C, North KE, Popkin BM, Gordon-Larsen P. Association of adolescent obesity with risk of severe obesity in adulthood. JAMA 2010;304:2042-2047.
14. Epstein LH, Valoski AM, Kalarchian MA, McCurley J. Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Obes Res 1995;3:411-417.
15. Johnston CA, Tyler C, Palcic JL et al. Smaller weight changes in standardized body mass index in response to treatment as weight classification increases. J Pediatr 2011;158:624-627.
16. James WP, Caterson ID, Coutinho W et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-917.
17. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293:2873-2883. (Pubitemid 41029141)
18. Metformin Extended Release Treatment of Adolescent Obesity. A 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010;164:116-123.
19. Yanovski JA, Krakoff J, Salaita CG et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011;60:477-485.
20. Buse JB, Drucker DJ, Taylor KL et al.; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-1261.
21. Rosenstock J, Klaff LJ, Schwartz S et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173-1175.
22. DeFronzo RA, Tripathy D, Schwenke DC et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115.
23. Selamet Tierney ES, Newburger JW, Gauvreau K et al. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr 2009;154:901-905.
24. Weiss R, Taksali SE, Tamborlane WV et al. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care 2005;28: 902-909. (Pubitemid 40434493)
25. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010;23:334-339.
26. Viner RM, Hsia Y, Tomsic T, Wong IC. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obes Rev 2010;11:593-602.